However, patients treated with Ada showed a trend towards more activated T cells (median 26.5%, IQR 14.4–33.6% for CD4 + and median 12.5%, IQR 6.9–18.3% for CD8 + ) as compared to those treated with Eta (median 14.6%, IQR 7–27.2% for CD4 + and median 4.8%, IQR 2.5–13.9% for CD8 + ) (p = 0.16 for CD4 + and p = 0.25 for CD8 + ; Fig. 2c ).
← all excerpts
Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases.
1
—
—